These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 2351315)

  • 41. Ovarian carcinosarcomas: clinicopathological prognostic factors and evaluation of chemotherapy regimens containing platinum.
    Cicin I; Saip P; Eralp Y; Selam M; Topuz S; Ozluk Y; Aydin Y; Topuz E
    Gynecol Oncol; 2008 Jan; 108(1):136-40. PubMed ID: 17936342
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cyclophosphamide and cisplatinum combination chemotherapy for the treatment of epithelial ovarian carcinoma.
    Hahn K; Magrina JF; Masterson BJ
    Int J Gynaecol Obstet; 1985 Dec; 23(6):509-13. PubMed ID: 2868947
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prognostic role and predictors of complete pathologic response to neoadjuvant chemotherapy in primary unresectable ovarian cancer.
    Petrillo M; Zannoni GF; Tortorella L; Pedone Anchora L; Salutari V; Ercoli A; Margariti PA; Scambia G; Fagotti A
    Am J Obstet Gynecol; 2014 Dec; 211(6):632.e1-8. PubMed ID: 24954656
    [TBL] [Abstract][Full Text] [Related]  

  • 44. International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma.
    Trimbos JB; Parmar M; Vergote I; Guthrie D; Bolis G; Colombo N; Vermorken JB; Torri V; Mangioni C; Pecorelli S; Lissoni A; Swart AM; ;
    J Natl Cancer Inst; 2003 Jan; 95(2):105-12. PubMed ID: 12529343
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A pilot study of three-cycle consolidation chemotherapy with paclitaxel and platinum in epithelial ovarian cancer patients with clinical complete response after paclitaxel and platinum chemotherapy.
    Lee SJ; Lee JW; Min JA; Park CS; Kim BG; Lee JH; Bae DS
    Int J Gynecol Cancer; 2006; 16(1):95-100. PubMed ID: 16445617
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ovarian epithelial tumors of low malignant potential.
    Chien RT; Rettenmaier MA; Micha JP; DiSaia PJ
    Surg Gynecol Obstet; 1989 Aug; 169(2):143-6. PubMed ID: 2756462
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Combination chemotherapy of intraperitoneal carboplatin and intravenous paclitaxel in suboptimally debulked epithelial ovarian cancer.
    Nagao S; Fujiwara K; Ohishi R; Nakanishi Y; Iwasa N; Shimizu M; Goto T; Shimoya K
    Int J Gynecol Cancer; 2008; 18(6):1210-4. PubMed ID: 18284454
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
    Barlow JJ; Lele SB
    Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Ten-year results of a randomised trial comparing cisplatin with cisplatin and cyclophosphamide in advanced, suboptimally debulked ovarian cancer.
    Marth C; Tropé C; Vergote IB; Kristensen GB
    Eur J Cancer; 1998 Jul; 34(8):1175-80. PubMed ID: 9849475
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Combined chemotherapy including platinum derivatives in the combined treatment of patients with stage-III to -IV ovarian cancer].
    Perevodchikova NI; Gorbunova VA; Grigorova TM; Kozachenko VP; Marenich AF
    Vestn Akad Med Nauk SSSR; 1986; (5):8-11. PubMed ID: 3755271
    [No Abstract]   [Full Text] [Related]  

  • 51. Neoadjuvant chemotherapy equalizes the optimal cytoreduction rate to primary surgery without improving survival in advanced ovarian cancer.
    Taşkın S; Güngör M; Ortaç F; Öztuna D
    Arch Gynecol Obstet; 2013 Dec; 288(6):1399-403. PubMed ID: 23775264
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
    Alberts DS; Liu PY; Hannigan EV; O'Toole R; Williams SD; Young JA; Franklin EW; Clarke-Pearson DL; Malviya VK; DuBeshter B
    N Engl J Med; 1996 Dec; 335(26):1950-5. PubMed ID: 8960474
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Ifosfamide, paclitaxel and cisplatin first-line chemotherapy in advanced, suboptimally debulked epithelial ovarian cancer.
    Papadimitriou CA; Kouroussis C; Moulopoulos LA; Vlahos G; Rodolakis A; Kiamouris C; Diakomanolis E; Gika D; Michalas S; Dimopoulos MA
    Cancer; 2001 Oct; 92(7):1856-63. PubMed ID: 11745258
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis.
    Chang SJ; Hodeib M; Chang J; Bristow RE
    Gynecol Oncol; 2013 Sep; 130(3):493-8. PubMed ID: 23747291
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Management of epithelial ovarian neoplasms using a platinum-based regimen: a 10-year experience.
    Belinson JL; Lee KR; Jarrell MA; McClure M
    Gynecol Oncol; 1990 Apr; 37(1):66-73. PubMed ID: 2323615
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: a multivariate analysis of survival for 100 consecutively treated patients.
    Stiff PJ; Bayer R; Kerger C; Potkul RK; Malhotra D; Peace DJ; Smith D; Fisher SG
    J Clin Oncol; 1997 Apr; 15(4):1309-17. PubMed ID: 9193322
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
    Tropé CG; Elstrand MB; Sandstad B; Davidson B; Oksefjell H
    Eur J Cancer; 2012 Sep; 48(14):2146-54. PubMed ID: 22382201
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outpatient taxol and carboplatin chemotherapy for suboptimally debulked epithelial carcinoma of the ovary results in improved quality of life: an Eastern Cooperative Oncology Group Phase II Study (E2E93).
    Schink JC; Weller E; Harris LS; Cella D; Gerstner J; Falkson C; Wadler S
    Cancer J; 2001; 7(2):155-64. PubMed ID: 11324769
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: Safety and effectiveness.
    da Costa Miranda V; de Souza Fêde ÂB; Dos Anjos CH; da Silva JR; Sanchez FB; da Silva Bessa LR; de Paula Carvalho J; Filho EA; de Freitas D; Del Pilar Estevez Diz M
    Gynecol Oncol; 2014 Feb; 132(2):287-91. PubMed ID: 24333355
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Long term survival by cytoreductive surgery to less than 1 cm, induction weekly cisplatin and monthly cisplatin, doxorubicin, and cyclophosphamide therapy in advanced ovarian adenocarcinoma.
    Baker TR; Piver MS; Hempling RE
    Cancer; 1994 Jul; 74(2):656-63. PubMed ID: 8033045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.